Nanoparticles to Sequester and Facilitate In Vivo Excretion of Lipophilic Molecules

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA9550-11-C-0083
Agency Tracking Number: F10B-T24-0132
Amount: $99,993.00
Phase: Phase I
Program: STTR
Awards Year: 2011
Solicitation Year: 2010
Solicitation Topic Code: AF10-BT24
Solicitation Number: 2010.B
Small Business Information
8100 Shaffer Parkway, Suite #130, Littleton, CO, -
DUNS: 148034408
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Steve Arzberger
 Program Manager
 (303) 792-5615
 stevea@adatech.com
Business Contact
 Clifton Brown, Jr.
Title: President&CEO
Phone: (303) 792-5615
Email: cliffb@adatech.com
Research Institution
 University of Nevada
 Kenneth H Sc.D.
 Microbiology&Immunology
199 / School of Medicine
Reno, NV, 89557-0046
 (775) 327-5255
 Nonprofit college or university
Abstract
ABSTRACT: Mycotoxins are lipophilic agents derived from fungus that pose a significant public health problem around the world. The effects of mycotoxins include loss of human and animal life, increased healthcare and veterinary costs, reduced livestock production, and disposal of contaminated foods and feeds. Mycotoxins, such as aflatoxin and T-2 mycotoxins, have been reported to be weaponized as terrorism agents, suggesting the possibility of future deployment against military personnel is a real and present danger. Unfortunately, no effective treatment for mycotoxin exposure in either the acute or chronic setting currently exists. As a result, the United States Air Force has identified the need to fabricate a nanoparticle therapeutic that can sequester and then facilitate the excretion of mycotoxins. To address this need, ADA Technologies Inc. (ADA; Littleton, CO) and Professor Kenneth W. Hunter (University of Nevada at Reno) propose the development of nanoparticles with surface-bound biomolecules for the intravenous binding of lipophilic molecules, sequestration, and excretion from the human body BENEFIT: The proposed program will result in a nanoparticle therapeutic with the demonstrated ability of tightly binding and sequestering lipophilic molecules in solution. The result of the proposed program is anticipated to be the first commercial therapeutic for exposure to fungal toxins. Additional commercial applications may include diagnostics, sensors, and tools for the identification of various harmful molds.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government